Metacrine Inc (MTCR) Peer Comparison
$0.58
$-0.01
(-1.29%)
As on 20-Jun-2023 15:11EDT
Market cap
$25 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
0.4
Div. Yield
0 %
Edit
| Metacrine Inc (MTCR) | Medpace Holdings (MEDP) | Exelixis (EXEL) | Arrowhead Pharmaceuticals (ARWR) | Halozyme Therapeutics (HALO) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
25 | 16,765 | 13,492 | 11,994 | 11,957 |
Revenue ($ Mln) |
-- | 2,782 | 2,436 | 670 | 1,664 |
Net Profit ($ Mln) |
-39.32 | 491.50 | 860.62 | -319.95 | 413.60 |
Net Margin (%) |
-- | 17.67 | 35.33 | -47.79 | 24.86 |
RoE (%) |
-94.16 | 110.09 | 42.98 | -71.14 | 430.03 |
Price to Earnings |
-- | 35.25 | 17.40 | -- | 30.89 |
Price-To-Book |
0.40 | 39.29 | 7.42 | 26.87 | 84.52 |
Income Statement ($ Mln)
| Metacrine Inc (MTCR) | Medpace Holdings (MEDP) | Exelixis (EXEL) | Arrowhead Pharmaceuticals (ARWR) | Halozyme Therapeutics (HALO) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
0.00 | 1,142.38 | 1,434.97 | 138.29 | 443.31 |
|
Cost of Revenue
|
0.00 | 814.22 | 52.87 | -- | 81.41 |
|
Gross Profit
|
-- | 328.16 | 1,382.10 | 138.29 | 361.90 |
|
Operating Expenses
|
36.13 | 129.54 | 1,095.43 | 287.32 | 86.00 |
|
Operating Profit (EBIT)
|
-36.51 | 198.62 | 286.67 | -149.04 | 275.90 |
|
Other Income
|
0.00 | 3.34 | -0.18 | 2.07 | -19.86 |
|
Profit before Tax
|
-38.19 | 201.85 | 294.15 | -140.85 | 248.52 |
|
Provision for Tax
|
1.13 | 20.00 | 63.09 | 0.00 | -154.19 |
|
Profit after Tax (Net Income)
|
-39.32 | 181.85 | 231.06 | -140.85 | 402.71 |
|
Minority Interest
|
0.00 | -- | -- | -- | -- |
|
Consolidated Profit
|
-38.19 | 181.85 | 231.06 | -140.85 | 402.71 |
Liabilities ($ Mln)
| Metacrine Inc (MTCR) | Medpace Holdings (MEDP) | Exelixis (EXEL) | Arrowhead Pharmaceuticals (ARWR) | Halozyme Therapeutics (HALO) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
37.07 | 952.93 | 2,210.62 | 408.82 | 196.95 |
|
Minority Interest
|
0.00 | -- | -- | -- | -- |
|
Non-Current Liabilities
|
13.44 | 149.79 | 68.03 | 154.79 | 790.33 |
|
Current Liabilities
|
4.53 | 557.22 | 337.59 | 146.54 | 117.15 |
|
Total Liabilities
|
79.99 | 1,659.94 | 2,616.24 | 710.15 | 1,104.43 |
Assets ($ Mln)
| Metacrine Inc (MTCR) | Medpace Holdings (MEDP) | Exelixis (EXEL) | Arrowhead Pharmaceuticals (ARWR) | Halozyme Therapeutics (HALO) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
0.00 | 969.02 | 781.49 | 325.55 | 178.14 |
|
Current Assets
|
55.04 | 690.91 | 1,834.75 | 384.60 | 926.29 |
|
Total Assets
|
79.99 | 1,659.94 | 2,616.24 | 710.15 | 1,104.43 |
|
Total Debt*
|
13.79 | 130.97 | 51.27 | 25.55 | 876.67 |
|
Net Current Assets
|
50.51 | 133.70 | 1,497.16 | 238.06 | 809.14 |
Cashflow ($ Mln)
| Metacrine Inc (MTCR) | Medpace Holdings (MEDP) | Exelixis (EXEL) | Arrowhead Pharmaceuticals (ARWR) | Halozyme Therapeutics (HALO) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-47.16 | 263.33 | 400.80 | 171.31 | 299.44 |
|
Cash Flow from Investing Activities
|
43.91 | -31.36 | -42.88 | -141.68 | -406.29 |
|
Cash from Financing Activities
|
27.77 | -44.45 | -14.80 | 11.31 | 77.87 |
|
Net Cash Inflow / Outflow
|
-- | 187.51 | 52.64 | 40.85 | -28.98 |
Ratios
Profitability Ratios
| Metacrine Inc (MTCR) | Medpace Holdings (MEDP) | Exelixis (EXEL) | Arrowhead Pharmaceuticals (ARWR) | Halozyme Therapeutics (HALO) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-72.25 | 18.14 | 11.03 | -30.71 | 49.66 |
|
ROE (%)
|
-94.16 | 20.68 | 11.30 | -32.36 | 231.44 |
|
ROA (%)
|
-57.22 | 11.92 | 9.72 | -22.85 | 47.82 |
|
EBIT Margin (%)
|
-- | -- | -- | -- | -- |
|
Net Margin (%)
|
-- | 15.87 | 16.10 | -100.35 | 95.10 |
|
Cash Profit Margin (%)
|
-- | -- | -- | -- | -- |
Growth Ratios
| Metacrine Inc (MTCR) | Medpace Holdings (MEDP) | Exelixis (EXEL) | Arrowhead Pharmaceuticals (ARWR) | Halozyme Therapeutics (HALO) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
-- | 0.23 | 0.45 | 0.57 | 0.66 |
|
EBIT Growth (%)
|
37.60 | -- | -- | -- | -- |
|
Net Profit Growth (%)
|
33.91 | 25.08 | 106.71 | -66.58 | 211.97 |
|
EPS Growth (%)
|
63.31 | 0.25 | 1.04 | -0.64 | 2.14 |
|
Book Value Growth (%)
|
-50.61 | -- | -- | -- | -- |
Valuation Ratios
| Metacrine Inc (MTCR) | Medpace Holdings (MEDP) | Exelixis (EXEL) | Arrowhead Pharmaceuticals (ARWR) | Halozyme Therapeutics (HALO) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-0.30 | 45.17 | 25.57 | -46.33 | 14.40 |
|
Price / Book Value
|
0.32 | 8.62 | 2.67 | 15.96 | 29.45 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
1.19 | 35.34 | 14.96 | -46.64 | 21.28 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Metacrine Inc (MTCR) | Medpace Holdings (MEDP) | Exelixis (EXEL) | Arrowhead Pharmaceuticals (ARWR) | Halozyme Therapeutics (HALO) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.34 | 0.14 | 0.02 | 0.06 | 4.45 |
|
Short term debt to equity ratio
|
0.03 | 0.17 | 0.00 | 0.01 | 0.45 |
|
Current Ratio
|
12.15 | 1.24 | 5.43 | 2.62 | 7.91 |
|
Quick Ratio
|
12.15 | -- | 5.35 | 2.59 | 7.45 |
|
Interest Coverage
|
-18.75 | 1,923.40 | -- | -23.01 | 36.66 |
Operating Efficiency Ratios
| Metacrine Inc (MTCR) | Medpace Holdings (MEDP) | Exelixis (EXEL) | Arrowhead Pharmaceuticals (ARWR) | Halozyme Therapeutics (HALO) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
-- | 16.32 | 19.70 | 7.42 | 20.52 |
|
Asset Turnover
|
0.00 | 0.75 | 0.60 | 0.22 | 0.53 |
|
Receivable days
|
-- | 55.54 | 56.45 | 14.66 | 77.74 |
|
Inventory Days
|
-- | 0.00 | 167.40 | -- | 257.19 |
|
Payable days
|
-- | 11.71 | 165.41 | -- | 7.78 |
|
Cash Conversion Cycle
|
-- | 48.64 | 58.44 | -- | 327.15 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
